Sjur Olsnes interviewed about the development in cancer research

Ellingsen EB, Aamdal E, Guren T, Lilleby W, Brunsvig PF, Mangsbo SM, Aamdal S, Hovig E, Mensali N, Gaudernack G, Inderberg EM (2022)
Durable and dynamic hTERT immune responses following vaccination with the long-peptide cancer vaccine UV1: long-term follow-up of three phase I clinical trials
J Immunother Cancer, 10 (5)
DOI 10.1136/jitc-2021-004345, PubMed 35613827

Skotland T, Iversen TG, Llorente A, Sandvig K (2022)
Biodistribution, pharmacokinetics and excretion studies of intravenously injected nanoparticles and extracellular vesicles: Possibilities and challenges
Adv Drug Deliv Rev, 186, 114326 (in press)
DOI 10.1016/j.addr.2022.114326, PubMed 35588953

Ianevski A, Giri AK, Aittokallio T (2022)
SynergyFinder 3.0: an interactive analysis and consensus interpretation of multi-drug synergies across multiple samples
Nucleic Acids Res (in press)
DOI 10.1093/nar/gkac382, PubMed 35580060

Smirnov P, Smith I, Safikhani Z, Ba-Alawi W, Khodakarami F, Lin E, Yu Y, Martin S, Ortmann J, Aittokallio T, Hafner M, Haibe-Kains B (2022)
Evaluation of statistical approaches for association testing in noisy drug screening data
BMC Bioinformatics, 23 (1), 188
DOI 10.1186/s12859-022-04693-z, PubMed 35585485

Ianevski A, Giri AK, Aittokallio T (2022)
SynergyFinder 3.0: an interactive analysis and consensus interpretation of multi-drug synergies across multiple samples
Nucleic Acids Res (in press)
DOI 10.1093/nar/gkac382, PubMed 35580060

Skotland T, Iversen TG, Llorente A, Sandvig K (2022)
Biodistribution, pharmacokinetics and excretion studies of intravenously injected nanoparticles and extracellular vesicles: Possibilities and challenges
Adv Drug Deliv Rev, 186, 114326 (in press)
DOI 10.1016/j.addr.2022.114326, PubMed 35588953